Edition:
India

Cytori Therapeutics Inc (CYTX.OQ)

CYTX.OQ on NASDAQ Stock Exchange Capital Market

0.35USD
12 Jan 2018
Change (% chg)

-- (--)
Prev Close
$0.35
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
256,883
52-wk High
$2.13
52-wk Low
$0.22

Chart for

About

Cytori Therapeutics, Inc. (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products. It is focused... (more)
No analyst recommendations are available for .

Overall

Beta: 2.49
Market Cap(Mil.): €18.78
Shares Outstanding(Mil.): 34.72
Dividend: --
Yield (%): --

Financials

BRIEF-Swissquote Bank Sells 188,426 Shares Of Cytori Therapeutics Inc's Common Stock Between Jan 9-11

* SWISSQUOTE BANK SA REPORTS OPEN MARKET SALE OF 188,426 SHARES OF CYTORI THERAPEUTICS INC'S COMMON STOCK BETWEEN JAN 9 AND JAN 11 - SEC FILING Source text: (http://bit.ly/2ExdrAg) Further company coverage:

11 Jan 2018

BRIEF-Swissquote Bank SA Reports 12 pct Passive Stake In Cytori Therapeutics As Of Dec. 29, 2017

* SWISSQUOTE BANK SA REPORTS 12 PERCENT PASSIVE STAKE IN CYTORI THERAPEUTICS INC AS OF DECEMBER 29, 2017 - SEC FILING‍​ Source text - (http://bit.ly/2CUutMr) Further company coverage:

09 Jan 2018

BRIEF-Cytori Therapeutics Inc ‍announces new investigator initiated U.S. clinical trial for hip osteonecrosis​

* Cytori Therapeutics Inc - ‍announced a new investigator initiated U.S. clinical trial for hip osteonecrosis​ Source text for Eikon: Further company coverage:

13 Nov 2017

BRIEF-Cytori reports Q3 loss per share $0.14

* Cytori reports third quarter 2017 business and financial results

10 Nov 2017

BRIEF-Cytori Therapeutics enters into an amendment to its existing loan and security agreement

* Cytori Therapeutics- On September 20, 2017, co entered into an amendment to its existing loan and security agreement, dated May 29, 2015 - SEC filing

22 Sep 2017

BRIEF-Cytori announces corporate restructuring & cost reduction plan

* Cytori announces corporate restructuring & cost reduction plan

02 Sep 2017

BRIEF-Cytori Therapeutics Q2 loss per share $0.19

* Cytori reports second quarter 2017 business and financial results

11 Aug 2017

BRIEF-Cytori announces top-line 24- and 48-week results

* Cytori announces top-line 24- and 48-week results from the star trial of habeo cell therapy in patients with scleroderma

24 Jul 2017

Earnings vs. Estimates